SEOUL: South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than US$231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years. The biotech arm of Samsung Group will start with manufacturing …
